Phase III success for efanesoctocog alfa sets up a filing in the near future, and a chance to seize market share from existing Factor VIII products, as well as Roche’s Hemlibra.

Sanofi will pay $17.5m up front to license candidates developed with Adagene’s SAFEbody platform, which can mask antibodies, enabling them to reach cancer targets in the tumor microenvironment.

Totals for aggregate deals and in the M&A, alliance and divestment categories were similar among the 10 busiest deal makers from 2020 to 2021, but COVID-19 may have driven a more hectic deal-making pace overall in 2020.

Daily notebook from the virtual J.P. Morgan Healthcare Conference: Alzheimer's rivals Roche and Lilly address their attempts at a different launch for their anti-amyloid therapies than Biogen's Aduhelm. GSK is buoyed by sotrovimab's efficacy against Omicron, BioNTech looks to the future of mRNA and Sanofi, Amgen and AbbVie defend their growth strategies.